STOCK TITAN

Relay Therapeutics CEO Sanjiv Patel sells 48,202 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Relay Therapeutics, Inc. (RLAY) President and CEO Sanjiv Patel sold 48,202 shares at a weighted-average sale price of $16.13 per share on November 19, 2026; trades ranged from $15.89 to $16.72. The sale was under a Rule 10b5-1 trading plan adopted October 30, 2025. Patel directly held 423,099 shares after the sale. The Patel Family Irrevocable Trust of 2019 held 199,548 shares, and The SSP Irrevocable Trust of 2020 held 687,355. Both trusts benefit family members and have an independent trustee; Patel disclaims beneficial ownership.

Insider Patel Sanjiv
Role President and CEO
Sold 48,202 shs ($777K)
Type Security Shares Price Value
Sale Common Stock F1, F2 48,202 $16.13 $777K
Holding Common Stock F3 -- -- --
Holding Common Stock F3 -- -- --
Holdings After Transaction: Common Stock — 423,099 shares (Direct); Common Stock — 199,548 shares (Indirect, By The Patel Family Irrevocable Trust of 2019); Common Stock — 687,355 shares (Indirect, By The SSP Irrevocable Trust of 2020)
Footnotes (3)
  1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
  2. F2. This transaction was executed in multiple trades at prices ranging from $15.89 to $16.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Shares sold 48,202 shares Sanjiv Patel's sale on November 19, 2026
Weighted-average sale price $16.13 per share Sale on November 19, 2026
Trade price range $15.89 to $16.72 per share Prices across the multiple trades on November 19, 2026
Direct shares following sale 423,099 shares Sanjiv Patel's direct holdings after the November 19, 2026 sale
Trust shares 199,548 shares Held by The Patel Family Irrevocable Trust of 2019 for family members; an independent trustee is trustee, and Patel disclaims beneficial ownership
Trust shares 687,355 shares Held by The SSP Irrevocable Trust of 2020 for family members; an independent trustee is trustee, and Patel disclaims beneficial ownership
Rule 10b5-1 trading plan regulatory
"effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RLAY shares did CEO Sanjiv Patel sell, and at what price?

Sanjiv Patel sold 48,202 shares at a weighted-average price of $16.13 per share on November 19, 2026. The trades ranged from $15.89 to $16.72 and were made under a Rule 10b5-1 trading plan adopted October 30, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Patel Sanjiv

(Last)(First)(Middle)
C/O RELAY THERAPEUTICS, INC.
60 HAMPSHIRE STREET

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/19/2026S(1)48,202D$16.13(2)423,099D
Common Stock199,548IBy The Patel Family Irrevocable Trust of 2019(3)
Common Stock687,355IBy The SSP Irrevocable Trust of 2020(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
2. This transaction was executed in multiple trades at prices ranging from $15.89 to $16.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
/s/ Soo-Yeun Lim, as attorney-in-fact11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading